{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007037","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.335620+00:00","generated_at":"2026-05-16T11:12:13.758641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer","bullets":["Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).","Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).","Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).","Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.","Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007037","json":"https://secwatch.observer/filing/0001193125-26-007037.json","markdown":"https://secwatch.observer/filing/0001193125-26-007037.md","text":"https://secwatch.observer/filing/0001193125-26-007037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/0001193125-26-007037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/psnl-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:12:13.758641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}